Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;14(2):151-9.
doi: 10.1038/tpj.2013.17. Epub 2013 Apr 30.

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent

V Michaud  1 , Y Kreutz  1 , T Skaar  1 , E Ogburn  1 , N Thong  1 , D A Flockhart  1 , Z Desta  1
Affiliations

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent

V Michaud et al. Pharmacogenomics J. 2014 Apr.

Abstract

Efavirenz increases CYP2C19- and CYP3A-mediated omeprazole metabolism. We hypothesized that CYP2C19 and CYP2B6 genetic polymorphisms influence the extent of induction of omeprazole metabolism by efavirenz. Healthy subjects (n=57) were administered a single 20 mg oral dose of omeprazole on two occasions: with a single 600 mg efavirenz dose; and after a 17-day treatment with efavirenz (600 mg per day). DNA was genotyped for CYP2C19*2, *3 and *17 alleles and CYP2B6*6, *4 and *9 alleles using Taqman assays. Omeprazole, its enantiomers and metabolites were measured by liquid chromatography/tandem mass spectrometry. Our results showed that efavirenz increased omeprazole clearances in all CYP2C19 genotypes in non-stereoselective manner, but the magnitude of induction was genotype dependent. Metabolic ratios of 5-hydroxylation of omeprazole were reduced in extensive and intermediate metabolizers of CYP2C19 (P<0.05). No significant associations were observed between CYP2B6 genotypes and induction by efavirenz on omeprazole metabolism. Our data indicate how interplays between drug interactions and CYP2C19 genetic variations may influence systemic exposure of CYP2C19 substrates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CYP2C19 phenotype frequency distribution of the log metabolic indexes of hydroxylation (A-C) and sulfoxidation (D) of omeprazole after a single 600 mg oral dose of efavirenz or during induction by multiple doses (600 mg/day for 17 days) of efavirenz. Racemic (A), R-omeprazole (B) and S-omeprazole (C) hydroxylation metabolic indexes are presented. The histograms were plotted using the log of omeprazole concentration divided by the metabolite concentration (5-hydroxyomeprazole or omeprazole sulfone) taken 3 hours after the administration of omeprazole. The probit plots were obtained by curve fitting of the log of omeprazole hydroxylation and sulfoxidation metabolic index from 57 subjects.
Figure 2
Figure 2
Association of CYP2C19 genotypes with omeprazole clearances when coadministered with a single dose or after multiple doses of efavirenz. Box plots of the clearance of A) racemate, B) R-omeprazole and C) S-omeprazole after single and multiple doses of efavirenz according to the CYP2C19 genotype status; ultra-rapid (UM; CYP2C19*17*17), extensive (EM; CYP2C19*1*1, CYP2C19*1*17), intermediate (CYP2C19*1*2 or *3) metabolizers. One-way ANOVA with Dunn’s comparison statistical analysis was performed to compare clearances between genotype groups and paired t-test was used to compare single dose vs. multiple doses for each individual genotype (*p<0.05 and **p<0.001).
Figure 3
Figure 3
Effects of CYP2B6 genetic polymorphisms on the log hydroxylation and sulfoxidation metabolic indexes of omperazole are presented after a single and multiple doses of efavirenz. The result showed that no significant difference was observed between all CYP2B6 genotype groups. One-way ANOVA with Dunn’s comparison statistical analysis was performed to compare log metabolic index between CYP2B6 genotype groups and paired t-test was used to compare single dose vs. multiple doses for each individual genotype. Percent changes (mean ±SD) of the log metabolic index for the A) 5-hydroxylation and B) sulfoxidation of omeprazole are presented, and no difference was observed between the CYP2B6 genotypes.
See this image and copyright information in PMC

References

    1. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287–300. - PubMed
    1. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos. 1999;27(11):1319–33. - PubMed
    1. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009;37(9):1793–6. - PMC - PubMed
    1. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007;8(6):547–58. - PubMed
    1. Bae SK, Jeong YJ, Lee C, Liu KH. Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica. 41(6):437–44. - PubMed

Publication types